AzTrials
AzTrials

Posterior Ischemic StrokeFORECAST-PCNCT07750015

Derivation and External Validation of the "FORECAST-PC" Prediction Scores

An observational study of Posterior Ischemic Stroke and Cerebral Infarction, run by Dr. med. Alexander Salerno, MD-PhD at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aims to develop and externally validate machine learning prediction models (FORECAST-PC) to determine 90-day functional outcomes for patients suffering from acute ischemic stroke in the posterior circulation who are selected for endovascular thrombectomy (EVT) Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
FORECAST-PC Prediction Models
How many people
732 participants
Where
1 siteSwitzerland
Study dates
1 Jan 2015to 31 Dec 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population comprises adult patients (older than 18 years) presenting with acute ischemic stroke (AIS) attributed to a radiologically confirmed posterior circulation large vessel occlusion. These individuals were treated at 14 international comprehensive stroke centers, with initial participation rooted in the European EVA-TRISP network. Patients were included if they were selected for endovascular thrombectomy (EVT) within 24 hours of the last known well time, regardless of whether they received prior intravenous thrombolysis (IVT) or were managed via mothership or drip-and-ship pathways. Participants were required to have a pre-stroke modified Rankin Scale (mRS) of 0 to 3. The cohort explicitly excludes patients whose strokes occurred in-hospital, patients treated beyond the 24-hour window, and patients treated prior to 2015.

Who may be able to join

  • Age > 18 years
  • Presentation with acute ischemic stroke (AIS) attributed to a radiologically confirmed posterior circulation occlusion
  • Selected for Endovascular Thrombectomy (EVT) according to the treating physician
  • Pre-stroke modified Rankin Scale (mRS) 0-3
  • EVT initiated or attempted within 24-hours of the last known well (LKW) time
  • Includes cases with/without prior intravenous thrombolysis (IVT), mothership, and drip-and-ship pathways

Who cannot join

  • EVT carried out beyond 24 hours from stroke onset
  • EVT performed secondarily after in-hospital worsening or stroke recurrence
  • In-hospital strokes (to avoid the confounding influence of prior systemic comorbidities and the acute event that necessitated initial admission)
  • Missing primary outcome data
  • Inconsistencies between descriptive dependence status and raw pre-stroke mRS
  • Stroke cases occurring prior to 2015 (to account for major changes in endovascular treatment techniques)

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Centre Hospitalier Universitaire Vaudois

    Lausanne, 1010

Other trials in Switzerland

About this study

Official title: Machine Learning Models Predict 90-Day Functional Outcome in Posterior Circulation Thrombectomy: Derivation and External Validation of the "FORECAST-PC" Prediction Scores

This study aims to develop and externally validate machine learning prediction models (FORECAST-PC) to determine 90-day functional outcomes for patients suffering from acute ischemic stroke in the posterior circulation who are selected for endovascular thrombectomy (EVT)

Read the detailed description

Outcome prediction after endovascular treatment (EVT) for posterior circulation (PC) acute ischemic stroke remains challenging, as current prognostic tools are often limited strictly to basilar artery occlusions or rely heavily on anterior circulation data. The FORECAST-PC study is an investigator-initiated, retrospective, international multicenter cohort study designed to develop and validate comprehensive PC outcome prediction models across key stages of the clinical pathway: Baseline, Pre-EVT, Immediately Post-EVT, and 24-hours Post-EVT. The models are derived from patients across three European centers and externally validated on an unseen cohort from 11 international centers to ensure robustness against geographic domain shifts and variations in clinical workflows. The clinical utility of these models is assessed using Decision Curve Analysis to demonstrate the net benefit of model-guided prognostication over standard clinical assumptions.

Being tested
FORECAST-PC Prediction Models
Keywords
Machine Learning, Posterior Cerebral Artery, Basilar Artery, Vertebral Artery, Endovasculat treatment, Thrombectomy, Prediction Algorithm
Medical subject headings
Cerebral Infarction, Cerebrovascular Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FORECAST-PC Prediction ModelsOther

    Application of machine learning gradient-boosted decision tree models (Full-Feature and Light versions) at admission and 24-hours to predict 90-day functional outcome.

Study groups in NCT07750015
Study groupRoleWhat they receive
Derivation cohortPatients with PC stroke selected for EVT from three primary training centers (Lausanne University Hospital, Bern University Hospital, and Charité-Universitätsmedizin Berlin).
Receives: Other: FORECAST-PC Prediction Models
External Validation CohortUnseen patients with PC stroke selected for EVT from 11 independent, world-wide comprehensive stroke centers
Receives: Other: FORECAST-PC Prediction Models

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Unfavorable Functional Outcome at 90 Days

    Defined as a dichotomized 90-day modified Rankin Scale (mRS) score of 3 to 6 (where 0-2 is favorable and 3-6 is unfavorable).

    Measured: 90 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Aug 2026
  2. Study start1 Jan 2015
  3. Primary completion31 Dec 2024
  4. Study completion31 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
732 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07750015
Sponsor's protocol ID
FORECAST-PC
Acronym
FORECAST-PC
Status last verified
Aug 2026
First submitted
2 Aug 2026
Last updated
6 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Posterior Ischemic Stroke and Cerebral Infarction, run by Dr. med. Alexander Salerno, MD-PhD at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Unfavorable Functional Outcome at 90 Days (time frame: 90 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in